Urogenital Neoplasms: 11350 Clinical Trials, Page 6 of 1135

Hide Studies Not Open or Pending

55

Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Condition(s):Ovarian Cancer; Ovarian and Fallopian Tube Cysts and Neoplasms; Neoplasms by Site; Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Carcinoma, Ovarian Epithelial; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Carcinoma; Anlotinib; PARP Inhibitors; BRCA1 Mutation; Angiogenesis; Antineoplastic Agents; BRCA2 MutationLast Updated:October 30, 2020Recruiting

56

Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

Condition(s):Ovarian Neoplasms; Fallopian Tube Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Carcinoma, Ovarian Epithelial; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Endocrine System Diseases; Gonadal Disorders; Carcinoma; Bevacizumab; Enzyme Inhibitors; Antineoplastic Agents; Molecular Mechanisms of Pharmacological Action; Angiogenesis; BRCA1 Mutation; BRCA2 Mutation; Homologous Recombination DeficiencyLast Updated:November 10, 2020Recruiting

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.